Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2013 Financial Results on Thursday, August 8, 2013
Date:8/1/2013

LYNBROOK, N.Y., Aug. 1, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, August 8, 2013 to report its second quarter 2013 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=95371.

A replay of the call will be available one hour after the end of the conference on August 8, 2013 until 9:00 a.m. EDT on August 19, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10032247. The archived webcast will be available for 90 days in the Investors section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. CCH is also in clinical development for the treatment of several additional promising indications. The U.S. Food & Drug Administration has accepted for filing Auxilium's supplemental Biologics License Application for XIAFLEX for the potential treatment of Peyronie's disease. The FDA is expected to take action on the application by September 6, 2013, and, if approved, XIAFLEX will be the first and only biologic treatment indicated for Peyronie's disease. Auxilium is also testing CCH for frozen shoulder syndrome (adhesive capsulitis) and cellulite. Auxilium has reported positive top-line data from a Phase IIa frozen shoulder study and expects to initiate a new clinical trial in the second half of 2013. BioSpecifics is currently managing the clinical development of CCH for the treatment of human and canine lipomas, which are both in Phase II clinical trials, with top-line data from both trials expected in the second half of 2013. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... , July 12, 2017 CarpalAID is a revolutionary new ... or surgery. Carpal tunnel syndrome affects more than 8 ... twice the rate of men. The common methods of treating CTS ... with uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn ...
(Date:7/11/2017)... July 11, 2017  Sysmex America, Inc., a ... testing equipment as well as middleware information systems ... to make quality assurance easier and more risk ... well known for the innovation that it delivers ... elevates quality assurance processes to a new level ...
(Date:7/10/2017)...  BDI Group subsidiary Pathway Purchasing Network, a ... serving specialty pharmacies, home infusion companies and physician ... value-added member programs designed to help organizations gain ... improve access and affordability for patients who rely ... Pathway has worked with ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... Dr. Jig Patel is pleased to announce openings ... without a referral. Understanding the difficulties that face people who are missing teeth ... permanent alternative to removable dentures and bridges. Not only does an implant improve oral ...
(Date:7/20/2017)... ... 19, 2017 , ... Western University of Health Sciences College ... grant to train predoctoral dental students in providing care to vulnerable children ages ... , The Predoctoral Pediatric Training Project (PPTP), a five-year grant, recognizes the curriculum ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/18/2017)... ... 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in the creation ... WORLDZ Summit, taking place in Hollywood from July 31-August 1, the Company’s Founder ... for both pediatric and adult patients, and how the path has led her to ...
(Date:7/18/2017)... , ... July 18, 2017 , ... The results of an international clinical trial, led ... therapy for a severe type of muscular dystrophy holds promise for a subgroup of patients. ... Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical ...
Breaking Medicine News(10 mins):